trending Market Intelligence /marketintelligence/en/news-insights/trending/9N2E7QfMKx9_Sh1guflO9w2 content esgSubNav
In This List

Fresenius Medical, NxStage merger further delayed pending FTC decision

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Fresenius Medical, NxStage merger further delayed pending FTC decision

The merger between Fresenius Medical Care AG & Co. KGaA and NxStage Medical Inc., a transaction valued at $2 billion, has been further delayed as the companies await a decision from the Federal Trade Commission.

The companies have been working with the regulatory agency to obtain clearance for the transaction, which was previously extended from Aug. 7, 2018, to Nov. 5, 2018. According to a Jan. 2 regulatory document from Fresenius Medical, the transaction is now expected to be completed in early 2019.

While Fresenius did not cite the federal government shutdown, the FTC has been closed and operating on a limited basis since Dec. 28, 2018.

Lawrence, Mass.-based NxStage, which develops medical devices for home dialysis, delivered $394 million in revenue in 2017. Its shareholders approved the merger and will receive $30 in cash for each common share of NxStage.

Germany-based Fresenius Medical provides services for kidney-related diseases, including dialysis treatment, diagnostics and outpatient care.